Alex Zhavoronkov (Insilico)
'Longevity as a service': Insilico spins off AI biotech that trains deep learning on anti-aging treatments
Since its inception in 2014, Insilico has racked up deal after deal on the promise that artificial intelligence can hasten drug development, touting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.